Bio Rad Laboratories Inc
NYSE:BIO
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
US |
Bio Rad Laboratories Inc
NYSE:BIO
|
8.1B USD | 22.3 | ||
US |
Thermo Fisher Scientific Inc
NYSE:TMO
|
228.4B USD | 34.4 | ||
US |
Danaher Corp
NYSE:DHR
|
186.3B USD | 20.7 | ||
US |
Agilent Technologies Inc
NYSE:A
|
43.3B USD | 33.6 | ||
US |
IQVIA Holdings Inc
NYSE:IQV
|
41.6B USD | 25.7 | ||
CH |
Lonza Group AG
SIX:LONN
|
37.2B CHF | 28.7 | ||
KR |
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 49.2 | ||
US |
Mettler-Toledo International Inc
NYSE:MTD
|
31.2B USD | 30.5 | ||
US |
West Pharmaceutical Services Inc
NYSE:WST
|
26.1B USD | 38.7 | ||
IE |
ICON PLC
NASDAQ:ICLR
|
25.6B USD | 26 | ||
US |
Waters Corp
NYSE:WAT
|
20.7B USD | 28.4 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.